The University of Chicago Header Logo

Connection

Stephen Hanauer to Infliximab

Back to Details
This is a "connection" page, showing publications Stephen Hanauer has written about Infliximab.
Stephen Hanauer
Connection Strength
3.126
Infliximab
  1. Editorial: safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor-induced colitis. Aliment Pharmacol Ther. 2023 01; 57(1):150-151.
    View in: PubMed
    Score: 0.214
  2. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer. 2021 11; 9(11).
    View in: PubMed
    Score: 0.199
  3. Checkpoint Inhibitor-Induced Colitis. Am J Gastroenterol. 2020 02; 115(2):202-210.
    View in: PubMed
    Score: 0.176
  4. Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. Clin Gastroenterol Hepatol. 2019 07; 17(8):1525-1532.e1.
    View in: PubMed
    Score: 0.160
  5. A Never Ending STORI. Clin Gastroenterol Hepatol. 2018 07; 16(7):1034-1036.
    View in: PubMed
    Score: 0.153
  6. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. Gastroenterology. 2016 Jun; 150(7):1568-1578.
    View in: PubMed
    Score: 0.134
  7. What to take from TREAT? Am J Gastroenterol. 2012 Sep; 107(9):1423-5.
    View in: PubMed
    Score: 0.105
  8. Management of inflammatory bowel disease: past, present and future. Expert Rev Clin Immunol. 2012 May; 8(4):303-5.
    View in: PubMed
    Score: 0.103
  9. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther. 2010 Aug; 32(3):384-93.
    View in: PubMed
    Score: 0.090
  10. Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow? Gastroenterol Clin Biol. 2009 Jun; 33 Suppl 3:S202-8.
    View in: PubMed
    Score: 0.084
  11. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut. 2007 Sep; 56(9):1181-3.
    View in: PubMed
    Score: 0.074
  12. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol. 2007 Apr; 102(4):794-802.
    View in: PubMed
    Score: 0.072
  13. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis. 2007 Jan; 13(1):2-11.
    View in: PubMed
    Score: 0.071
  14. General principles and pharmacology of biologics in inflammatory bowel disease. Gastroenterol Clin North Am. 2006 Dec; 35(4):757-73.
    View in: PubMed
    Score: 0.071
  15. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006 Mar; 63(3):433-42; quiz 464.
    View in: PubMed
    Score: 0.067
  16. Infliximab or cyclosporine for severe ulcerative colitis. Gastroenterology. 2005 Oct; 129(4):1358-9; author reply 1359.
    View in: PubMed
    Score: 0.065
  17. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease. Am J Gastroenterol. 2005 Jul; 100(7):1438-9.
    View in: PubMed
    Score: 0.064
  18. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004 Jul; 2(7):542-53.
    View in: PubMed
    Score: 0.060
  19. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004 Feb; 126(2):402-13.
    View in: PubMed
    Score: 0.058
  20. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004 Jan; 99(1):91-6.
    View in: PubMed
    Score: 0.058
  21. Emerging biologic therapies in inflammatory bowel disease. Rev Gastroenterol Disord. 2004; 4(2):66-85.
    View in: PubMed
    Score: 0.058
  22. Controversies with aminosalicylates in inflammatory bowel disease. Rev Gastroenterol Disord. 2004; 4(3):104-17.
    View in: PubMed
    Score: 0.058
  23. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies. Rev Gastroenterol Disord. 2004; 4 Suppl 3:S18-24.
    View in: PubMed
    Score: 0.058
  24. Considerations in the management of steroid-dependent Crohn's disease. Gastroenterology. 2003 Sep; 125(3):906-10.
    View in: PubMed
    Score: 0.056
  25. Immunogenicity of infliximab in Crohn's disease. N Engl J Med. 2003 May 22; 348(21):2155-6; author reply 2155-6.
    View in: PubMed
    Score: 0.055
  26. A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis. 2003 May; 9(3):176-8.
    View in: PubMed
    Score: 0.055
  27. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol. 2002 Dec; 97(12):2962-72.
    View in: PubMed
    Score: 0.053
  28. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002 May 04; 359(9317):1541-9.
    View in: PubMed
    Score: 0.051
  29. Biologics in peri-operative management of Crohn's disease. Acta Gastroenterol Belg. 2001 Apr-Jun; 64(2):191-2.
    View in: PubMed
    Score: 0.048
  30. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol. 2000 Dec; 95(12):3469-77.
    View in: PubMed
    Score: 0.047
  31. Evolutionary biologic therapy for inflammatory bowel disease. Curr Gastroenterol Rep. 1999 Dec; 1(6):467-9.
    View in: PubMed
    Score: 0.043
  32. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther. 1999 Sep; 13 Suppl 4:16-22; discussion 38.
    View in: PubMed
    Score: 0.043
  33. Updating the approach to Crohn's disease. Hosp Pract (1995). 1999 Aug 15; 34(8):77-8, 81-3, 87-93; discussion 94.
    View in: PubMed
    Score: 0.043
  34. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999 May; 5(2):119-33.
    View in: PubMed
    Score: 0.042
  35. Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clin Ther. 1998 Sep-Oct; 20(5):1009-28.
    View in: PubMed
    Score: 0.040
  36. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014 Nov; 63(11):1721-7.
    View in: PubMed
    Score: 0.029
  37. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011 Oct; 141(4):1194-201.
    View in: PubMed
    Score: 0.024
  38. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012 Feb; 18(2):201-11.
    View in: PubMed
    Score: 0.024
  39. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr; 106(4):644-59, quiz 660.
    View in: PubMed
    Score: 0.024
  40. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011 Feb; 106(2):199-212; quiz 213.
    View in: PubMed
    Score: 0.023
  41. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep; 15(9):1302-7.
    View in: PubMed
    Score: 0.021
  42. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009 Oct; 137(4):1250-60; quiz 1520.
    View in: PubMed
    Score: 0.021
  43. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007 Jun 19; 146(12):829-38.
    View in: PubMed
    Score: 0.018
  44. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol. 2006 May; 101(5):1030-8.
    View in: PubMed
    Score: 0.017
  45. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 08; 353(23):2462-76.
    View in: PubMed
    Score: 0.016
  46. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004 Oct; 99(10):1984-9.
    View in: PubMed
    Score: 0.015
  47. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001 Nov; 121(5):1088-94.
    View in: PubMed
    Score: 0.012
  48. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology. 2001 May; 120(6):1330-8.
    View in: PubMed
    Score: 0.012
  49. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001 May; 7(2):83-8.
    View in: PubMed
    Score: 0.012
  50. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999 Oct; 117(4):761-9.
    View in: PubMed
    Score: 0.011
  51. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999 May 06; 340(18):1398-405.
    View in: PubMed
    Score: 0.010
  52. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997 Oct 09; 337(15):1029-35.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.